Stephen J Moss Selected Research

Status Epilepticus (Complex Partial Status Epilepticus)

1/2023	Direct activation of KCC2 arrests benzodiazepine refractory status epilepticus and limits the subsequent neuronal injury in mice.
1/2022	Inhibiting with-no-lysine kinases enhances K+/Cl- cotransporter 2 activity and limits status epilepticus.
1/2016	Compromising KCC2 transporter activity enhances the development of continuous seizure activity.
3/2015	KCC2 activity is critical in limiting the onset and severity of status epilepticus.
12/2012	Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures.
10/2010	Tyrosine phosphorylation regulates the membrane trafficking of the potassium chloride co-transporter KCC2.
1/2008	Deficits in phosphorylation of GABA(A) receptors by intimately associated protein kinase C activity underlie compromised synaptic inhibition during status epilepticus.
12/2007	Disrupted dentate granule cell chloride regulation enhances synaptic excitability during development of temporal lobe epilepsy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen J Moss Research Topics

Disease

15	Epilepsy (Aura) 01/2022 - 10/2002
8	Status Epilepticus (Complex Partial Status Epilepticus) 01/2023 - 12/2007
8	Seizures (Absence Seizure) 01/2022 - 01/2010
6	Alzheimer Disease (Alzheimer's Disease) 08/2023 - 08/2003
6	Schizophrenia (Dementia Praecox) 01/2020 - 01/2007
4	Neoplasms (Cancer) 01/2024 - 01/2010
4	Substance-Related Disorders (Drug Abuse) 01/2017 - 10/2002
3	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2024 - 01/2017
3	Nervous System Diseases (Neurological Disorders) 08/2013 - 10/2004
2	Amyloid Plaque 08/2023 - 01/2022
2	Mood Disorders (Mood Disorder) 12/2020 - 01/2007
2	Bipolar Disorder (Manic Depressive Psychosis) 12/2020 - 10/2009
2	Fragile X Syndrome (Martin Bell Syndrome) 01/2019 - 01/2017
2	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2017 - 01/2017
2	Ischemia 08/2010 - 01/2007
1	Cystic Fibrosis (Mucoviscidosis) 01/2024
1	Ataxia (Dyssynergia) 12/2022
1	Hyperammonemia 01/2022
1	Major Depressive Disorder (Major Depressive Disorders) 12/2020
1	Postpartum Depression (Post-Natal Depression) 12/2020
1	Chorea (Rheumatic Chorea) 01/2020
1	Traumatic Brain Injuries (Traumatic Brain Injury) 11/2017
1	Autistic Disorder (Autism) 11/2017
1	Frontotemporal Dementia (Semantic Dementia) 01/2017
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/2017
1	Disruptive, Impulse Control, and Conduct Disorders (Kleptomania) 11/2016
1	Pathologic Processes 11/2016
1	Glioma (Gliomas) 10/2016
1	Idiopathic Generalized Epilepsy 07/2014
1	AIDS-Related Complex (ARC) 01/2014
1	Sleep Initiation and Maintenance Disorders (Insomnia) 11/2012
1	Inflammation (Inflammations) 09/2012
1	Memory Disorders (Memory Loss) 09/2012
1	Cushing Syndrome 12/2011
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2010
1	Encephalitis (Encephalitis, Rasmussen) 01/2010

Drug/Important Bio-Agent (IBA)

7	gamma-Aminobutyric Acid (GABA)IBA 10/2018 - 12/2007
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2004
5	EnzymesIBA 08/2023 - 08/2003
5	BenzodiazepinesIBA 01/2023 - 11/2012
5	K Cl- CotransportersIBA 01/2022 - 07/2014
4	Amyloid (Amyloid Fibrils)IBA 08/2023 - 03/2004
3	Diazepam (Valium)FDA LinkGeneric 01/2022 - 08/2013
3	ChloridesIBA 11/2017 - 12/2007
3	Aminobutyrates (Aminobutyric Acid)IBA 01/2017 - 09/2012
3	GABA-A Receptors (GABA(A) Receptor)IBA 11/2012 - 01/2008
3	GABA-B ReceptorsIBA 01/2010 - 10/2004
2	Phosphotransferases (Kinase)IBA 01/2024 - 01/2022
2	Propofol (Diprivan)FDA LinkGeneric 12/2022 - 08/2013
2	Glutamic Acid (Glutamate)FDA Link 01/2022 - 10/2016
2	Kainic Acid (Kainate)IBA 01/2022 - 12/2015
2	Amyloid beta-PeptidesIBA 01/2022 - 03/2004
2	4-Aminopyridine (4 Aminopyridine)FDA Link 01/2022 - 01/2016
2	ConvulsantsIBA 12/2020 - 12/2015
2	NeurosteroidsIBA 12/2020 - 01/2019
2	DNA-Binding Proteins (DNA Binding Protein)IBA 01/2017 - 01/2017
2	Anesthetics (Anesthetic Agents)IBA 11/2016 - 08/2013
2	Pilocarpine (Ocusert)FDA LinkGeneric 10/2010 - 12/2007
2	Hypnotics and Sedatives (Sedatives)IBA 01/2007 - 10/2002
2	Anti-Anxiety Agents (Anxiolytics)IBA 01/2007 - 10/2002
2	Messenger RNA (mRNA)IBA 03/2004 - 08/2003
1	Peptides (Polypeptides)IBA 08/2023
1	Ethanol (Ethyl Alcohol)IBA 12/2022
1	protein kinase modulatorIBA 12/2022
1	apremilastIBA 12/2022
1	N- (2- (4- bromocinnamylamino)ethyl)- 5- isoquinolinesulfonamide (h89)IBA 12/2022
1	AmmoniaIBA 01/2022
1	WNK463IBA 01/2022
1	nasIBA 01/2022
1	Lysine (L-Lysine)FDA Link 01/2022
1	zuranoloneIBA 12/2020
1	brexanoloneIBA 12/2020
1	Small Interfering RNA (siRNA)IBA 01/2020
1	Threonine (L-Threonine)FDA Link 01/2019
1	Glutamate-Ammonia Ligase (Glutamine Synthetase)IBA 01/2019
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2019
1	LipidsIBA 01/2018
1	Apolipoproteins E (ApoE)IBA 01/2018
1	RNA (Ribonucleic Acid)IBA 01/2017
1	Potassium Channels (Potassium Channel)IBA 01/2017
1	GTP-Binding Proteins (G-Protein)IBA 01/2017
1	LigandsIBA 11/2016
1	Potassium Chloride FDA LinkGeneric 10/2016
1	Anticonvulsants (Antiepileptic Drugs)IBA 10/2016
1	Bumetanide (Bumex)FDA LinkGeneric 10/2016
1	Carrier Proteins (Binding Protein)IBA 01/2016
1	Vesicular Transport Adaptor ProteinsIBA 01/2016
1	Alanine (L-Alanine)FDA Link 03/2015
1	Immunoglobulin E (IgE)IBA 07/2014
1	AMPA Receptors (AMPA Receptor)IBA 01/2014
1	Serine (L-Serine)FDA Link 08/2011
1	Neurotransmitter Agents (Neurotransmitter)IBA 08/2011
1	D-Amino-Acid Oxidase (D-Amino Acid Dehydrogenase)IBA 08/2011
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 08/2011
1	Tyrosine (L-Tyrosine)FDA Link 10/2010
1	Glutamate Receptors (Glutamate Receptor)IBA 08/2010
1	AntibodiesIBA 01/2010
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 01/2010

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2017
1	Immunotherapy 01/2010